Important Matters - Pritchard has achieved a significant breakthrough in LCP film technology, being the only company in China to do so, and is collaborating with overseas clients for applications in brain-computer interfaces [1] - Zhongtian Rocket's small guided rocket products primarily serve military trade, with product gross margins fluctuating between 35% and 40% [1] - CIMC's subsidiary is providing liquid oxygen storage tanks and other equipment in the commercial aerospace sector, with expected revenue and orders exceeding 100 million yuan by 2025 [1] - Gaode Infrared is supplying infrared detector cores for commercial aerospace and satellite applications [1] - Zhongfu Shenying's M55J-grade carbon fiber is undergoing application verification in satellite structural components [1] Investment and Operations - Dazhong Mining plans to invest 3.688 billion yuan in a 20 million tons per year lithium mining and selection project [1] - Zhongkuang Resources has commenced trial production for a high-purity lithium salt project with an annual output of 30,000 tons [1] - Cuiwei Co., Ltd. has indirectly invested 150 million yuan in Super Fusion through its subsidiary fund [1] - Huagong Technology has launched a self-developed silicon photonic chip for 1.6T optical modules [1] - Gaomei Co., Ltd. has formed small batch orders for composite tungsten wire tendon ropes [1] - Xinlitai's innovative drug SAL0145 injection has had its clinical trial application accepted [1] - Hengrui Medicine's innovative drug Rilaforpu α injection has been approved for market launch, with no similar products approved domestically or internationally [1] - Yifan Pharmaceutical's wholly-owned subsidiary has received a registration acceptance notice for Yihuang Decoction granules, with no similar products from the same prescription available domestically [1] Partnerships and Collaborations - Taisheng Wind Power has formed strategic partnerships with multiple arrow manufacturers [2] - Guangqi Technology's subsidiary has signed batch production contracts totaling 264 million yuan for metamaterials with four clients [2] - Lingyi Intelligent Manufacturing has reached a strategic cooperation agreement with Qiangnao Technology [2] Performance - Zhongke Lanyun expects a net profit increase of 367%-377% year-on-year in 2025, driven by significant fair value changes from investments in Moer Thread and Muxi Co., Ltd. [2] - Kangchen Pharmaceutical anticipates a net profit increase of 243%-315% year-on-year in 2025 [2] - Chuanjinno expects a net profit increase of 144%-173% year-on-year in 2025 [2] - Beifang Navigation forecasts a net profit increase of 86.32%-137.14% year-on-year in 2025 [2]

Group 1 - Heng Rui Medicine's subsidiary received approval for the innovative drug Rilaforpu α injection (brand name: Aizeli®), marking it as the world's first PD-L1/TGF-βRII bispecific antibody fusion protein approved for advanced gastric cancer treatment [1] - The approval highlights the innovative mechanism of Aizeli, which overcomes the immune suppression microenvironment, filling a clinical treatment gap and showcasing the global competitiveness of domestic innovative drugs [1] Group 2 - Anlong Bio announced the completion of nearly 100 million yuan in B+ round financing, with investments from Beijing's pharmaceutical health industry investment fund and the Shunyi Airport Industrial Fund [2] - The company also established an international strategic cooperation agreement in the small nucleic acid drug field with a NASDAQ-listed company, with a cooperation scale exceeding 100 million USD, indicating significant progress in international business development [2] Group 3 - Yifan Pharmaceutical's wholly-owned subsidiary received a drug registration acceptance notice for Yihuang Decoction granules, which is the company's first classic prescription variety aimed at treating kidney deficiency and dampness [3] - The acceptance of this classic prescription is expected to accelerate approval and broaden the company's traditional Chinese medicine innovation pipeline due to the scarcity of similar competing products [3] Group 4 - Weili Medical projected a net profit decrease of 57% to 66% for the fiscal year 2025, estimating a profit of 75 million to 95 million yuan, a decline of 144 million to 124 million yuan compared to the previous year [4] - The profit drop is attributed to subsidiary performance issues and goodwill impairment, indicating short-term profit pressure, with the recovery of core business and overseas capacity release being critical for future performance [4] Group 5 - Borui Bio submitted its IPO application for listing in Hong Kong, with the prospectus now publicly available [5] - The company has eight commercialized products, including two innovative drugs and six mature products, with significant revenue derived from Adalimumab and Zibotuzumab [5] - As of September 30, 2025, Borui Bio reported nearly 1.2 billion yuan in cash reserves, and the company completed a financing round of 540 million yuan in 2022, achieving a post-investment valuation of 13.5 billion yuan [5]

Core Viewpoint - The company is shifting its strategy from primarily self-research to integrating external research resources, exemplified by the introduction of the innovative cancer drug ACT001, aiming to accelerate commercialization and enrich its pipeline [1][3]. Group 1: Company Strategy - The company has signed exclusive agreements to obtain the rights for the development, production, and commercialization of ACT001 in specific regions and indications, requiring an initial payment of 100 million RMB and potential milestone payments [1][2]. - The company aims to establish a systematic mechanism for external project introduction, evaluation, and integration, focusing on enhancing its pipeline and accelerating commercialization efforts [3]. Group 2: Drug Development and Clinical Trials - ACT001 is a novel class 1 innovative drug developed by Shangde Pharmaceutical, which has undergone 8 years of preclinical development and 8 years of clinical trials, with over 400 patients participating in exploratory I-II phase clinical trials globally [2]. - ACT001 targets cancer stem cells selectively and can be used in combination with other drugs, making it the first drug in development targeting both STAT3 and NF-κB with favorable safety and pharmacokinetic profiles [2]. Group 3: Market Potential - According to the National Cancer Center, lung cancer is the most prevalent and deadly cancer in China, with approximately 1.0606 million new cases in 2022, representing 22% of all malignancies [4]. - The company estimates that there are over 90,000 new patients with small cell lung cancer brain metastases annually, indicating a significant potential market for ACT001, although pricing remains uncertain [4].

Group 1 - The core point of the article is that Yifan Pharmaceutical (002019) has reported a total of 49,535 shareholders as of December 19, 2025 [1]

Core Viewpoint - Yifan Pharmaceutical's wholly-owned subsidiary has received a production registration acceptance notice for Yihuang Decoction Granules, marking a significant step in the company's product development as it is the first classic prescription variety registered by the company [1] Company Summary - Yifan Pharmaceutical (002019.SZ) announced that its subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd., received the acceptance notice from the National Medical Products Administration for the production registration of Yihuang Decoction Granules on January 6, 2026 [1] - Yihuang Decoction Granules are indicated for kidney strengthening and dampness clearing, representing a new product offering in the company's portfolio [1] - As of the report date, there are no other products in the domestic market derived from the same prescription, with only one other company currently undergoing the application review process [1] Industry Summary - The acceptance of the registration application indicates a potential market opportunity for Yihuang Decoction Granules, as it is a unique product with no direct competitors in the domestic market [1] - The drug will proceed to the drug review center for evaluation and approval following the acceptance by the regulatory authority, highlighting the regulatory pathway for new pharmaceutical products in the industry [1]

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd., received the acceptance notice for the domestic production drug registration application for Yihuang Decoction Granules from the National Medical Products Administration on January 6, 2026 [1] Group 1 - The company has received regulatory approval for a new product, indicating progress in its product pipeline [1] - The acceptance notice is a significant step towards the commercialization of Yihuang Decoction Granules [1]

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd., received the acceptance notice for the domestic production drug registration application for Yihuang Decoction Granules from the National Medical Products Administration on January 6, 2026 [1] Group 1 - The company has received regulatory approval for a new product, indicating progress in its product pipeline [1] - The acceptance notice is a significant step towards the commercialization of Yihuang Decoction Granules [1] - This development may enhance the company's market position in the pharmaceutical industry [1]

Core Viewpoint - Yifan Pharmaceutical (002019) announced that its wholly-owned subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd., received the acceptance notice for the domestic production drug registration application for Yihuang Decoction Granules from the National Medical Products Administration on January 6, 2026. This product is the first classic formula variety registered by the company, aimed at kidney strengthening and dampness clearing [1]. Company Summary - Yifan Pharmaceutical's subsidiary has successfully progressed in the drug registration process, indicating a positive step towards bringing Yihuang Decoction Granules to market [1]. - The product is positioned to address specific health needs, focusing on kidney health and the elimination of dampness, which may enhance the company's product portfolio [1].

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) has received a registration acceptance notice from the National Medical Products Administration for its product Yihuang Decoction Granules, marking a significant step in its product development strategy [1] Group 1: Product Development - Yifan Pharmaceutical's wholly-owned subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd., received the registration acceptance notice on January 6, 2026 [1] - Yihuang Decoction Granules is the first classic formula product registered by the company, based on a prescription from the "First Batch of Ancient Classic Formulas Catalog" published by the National Administration of Traditional Chinese Medicine in April 2018 [1] - The formula is derived from the Qing Dynasty work "Fu Qingzhu Nüke" by Fu Shan, and is indicated for treating kidney deficiency with damp-heat symptoms [1] Group 2: Indications and Usage - The primary function of Yihuang Decoction Granules is to solidify the kidney and stop abnormal discharge, as well as to clear heat and eliminate dampness [1] - It is specifically used for symptoms such as excessive, thick, yellow discharge resembling concentrated tea, with a foul odor, red tongue, and yellow greasy coating [1]

亿帆医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）全资子公司宿州亿帆药业有限 公司于 2026 年 1 月 6 日收到国家药品监督管理局（以下简称"药监局"）签发 的易黄汤颗粒境内生产药品注册上市许可申请《受理通知书》。现将相关情况公 告如下： 一、申请注册药品的基本情况 受理号：CXZS2600002 药品名称：易黄汤颗粒 申请事项：境内生产药品注册上市许可 规格：每袋相当于饮片47.90g 证券代码：002019 证券简称：亿帆医药 公告编号：2026-005 易黄汤颗粒是公司申报注册的第一个经典名方品种，品种处方为国家中医药 管理局 2018 年 4 月发布的《古代经典名方目录（第一批）》中的第 85 首处方， 出自清代傅山《傅青主女科》，其功能主治为：固肾止带，清热祛湿。用于肾虚 湿热带下证。症见带下黏稠量多，色黄如浓茶汁，其气腥秽，舌红，苔黄腻。 截至本报告披露日，国内尚无与易黄汤颗粒出自同一处方产品上市，除本公 司外，仅有 1 家企业处于申请上市 ...